Metabolic syndrome in antipsychotic naïve patients with schizophrenia: Pooled analysis of data from three Indian studies

Early Intervention in Psychiatry

Volumn 9, Issue 5, 2015, Pages 357-362

  Grover, Sandeep ^a   Nebhinani, Naresh ^b   Padmavati, Ramachandran ^c   Chadda, Rakesh K ^d   Tirupati, Srinivasan ^e   Pallava, Abhishek ^d  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c SCHIZOPHRENIA RESEARCH FOUNDATION   (India)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Drug na ve; Metabolic syndrome; Schizophrenia

Indexed keywords

GLUCOSE; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; CAUCASIAN; COMORBIDITY; META ANALYSIS; MIDDLE AGED; PSYCHOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COMORBIDITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INDIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84940898741     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12117     Document Type: Article

References (35)

1. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121.
2. Tihonen J, Lonnqvist J, Wahlbeck K etal. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627.
3. Lakka HM, Laaksonen DE, Lakka TA etal. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
4. Mottillo S, Filion KB, Genest J etal. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132.
5. Saari KM, Lindeman SM, Viilo KM etal. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005; 66: 559-563.
6. De Hert MA, van Winkel R, van Eyck D etal. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83: 87-93.
7. Toalson P, Ahmed S, Hardy T, Kabinoff G. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 2004; 6: 152-158.
8. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry 2004; 184: S76-S79.
9. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51: 480-491.
10. Lamberti JS, Olson D, Crilly JF etal. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; 163: 1273-1276.
11. Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007; 191: 23-29.
12. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 2010; 10: 209-216.
13. Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six week prospective study in Indian female patients. Schizophr Res 2007; 95: 247.
14. Saddichha S, Ameen S, Akhtar S. Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics. Aust N Z J Psychiatry 2007; 41: 629.
15. De Hert M, Schreurs V, Sweers K etal. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101: 295-303.
16. Patel JK, Buckley PF, Woolson S etal.; for the CAFE investigators. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111: 9-16.
17. Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res 2010; 121: 199-202.
18. Phutane VH, Tek C, Chwastiak L etal. Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention? Schizophr Res 2011; 127: 257-261.
19. Grover S, Nebhinani N, Chakrabarti S, Parakh P, Ghormode D. Metabolic syndrome in antipsychotic naïve patients diagnosed with schizophrenia. Early Interv Psychiatry 2012; 6: 326-331.
20. Pallava A, Chadda RK, Sood M, Lakshmy R. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India. Nord J Psychiatry 2012; 66: 215-221.
21. Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry 2011; 53: 128-133.
22. Vinay HR, Keerthi Sundar GS, Behere RV etal. Effect of risperidone on metabolic parameters in antipsychotic-naïve schizophrenia: a prospective one year follow-up study. Asian J Psychiatry 2011; 4: 73-74.
23. Saddichha S, Narayana M, Shahul A, Sayeed A. Metabolic syndrome in first episode schizophrenia: a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008; 101: 266-272.
24. Alberti KG, Eckel RH, Grundy SM etal. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of obesity. Circulation 2009; 120: 1640-1645.
25. Benseñor IM, Brunoni AR, Pilon LA, Goulart AC, Busatto GF, Lotufo PA. Cardiovascular risk factors in patients with first-episode psychosis in São Paulo, Brazil. Gen Hosp Psychiatry 2012; 34: 268-275.
26. Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 2013; 16: 987-995.
27. Grover S, Nebhinani N, Chakrabarti S etal. Comparative study of prevalence of metabolic syndrome in bipolar disorder and schizophrenia from North India. Nord J Psychiatry 2014; 68: 72-77.
28. Grover S, Nebhinani N, Chakrabarti S, Avasthi A, Kulhara P. Metabolic syndrome among patients receiving clozapine: a preliminary estimate. Indian J Pharmacol 2011; 43: 591-595.
29. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21: 93-98.
30. Nebhinani N, Grover S, Chakrabarti S, Kate N, Avasthi A. A longitudinal study of change in prevalence of metabolic syndrome and metabolic disturbances 3 months after Clozapine therapy. J Ment Health Human Behav 2013; 18: 9-17.
31. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 2013; 39: 295-305.
32. Sawant A, Mankeshwar R, Shah S etal. Prevalence of metabolic syndrome in urban India. Cholesterol 2011; 2011: 920983.
33. World Bank Report on Malnutrition in India. 2009. [Cited 15 Jul 2013.] Available from URL: http://web.worldbank.org/WBSITE/EXTERNAL/COUNTRIES/SOUTHASIAEXT/0, contentMDK:20916955~pagePK:146736~piPK:146830~theSitePK:223547, 00.html
34. De Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8: 15-22.
35. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002; 71: 239-257.